GLYCEROLIPIDS & PROSTAGLANDIN SYNTHESIS IN EYE TISSUES
甘油脂
基本信息
- 批准号:3258784
- 负责人:
- 金额:$ 15.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1981
- 资助国家:美国
- 起止时间:1981-12-01 至 1997-03-31
- 项目状态:已结题
- 来源:
- 关键词:G protein anticholinergic agent arachidonate biological signal transduction eicosanoid metabolism enzyme activity enzyme inhibitors eye pharmacology fatty acid biosynthesis iris laboratory rabbit membrane lipids muscle contraction phospholipase A2 phospholipase C phospholipase D prostaglandins protein kinase C protein purification radiotracer receptor coupling receptor sensitivity second messengers stimulant /agonist trabecular meshwork uvea ciliary body
项目摘要
DESCRIPTION (Investigator's Abstract): The long-term goal of this research
is to elucidate the regulatory mechanisms involved in arachidonic acid (AA)
liberation and eicosanoid biosynthesis in the iris-ciliary body (ICB) and
other ocular tissues. The central hypothesis to be tested is that
phospholipase A2 (PLA2) activation is a major source for AA release in the
ICB. This represents a logical pursuit of the findings obtained during the
current budget period. ICB is the major source of eicosanoid synthesis in
the eye. The investigators and others have reported that activation of the
ICB with various agonists, including carbachol, PGE2alpha, substance P,
endothelin-1, and PAF results in the rapid hydrolysis of
polyphosphoinositides into IP3 and DAG, the two second messengers, and the
concomitant liberation from membrane phospholipids of AA for eicosanoid
biosynthesis. The investigators have found that the generation of these
phospholipid-derived second messengers and the formation of cAMP and their
physiological consequences to be species dependent. While the involvement
of phospholipases (A2,C,D) in AA release has been documented in several
tissues, including ICB, the precise mechanism underlying the stimulated
release of this polyunsaturated fatty acid remains undefined. This is also
true of the phospholipid source of AA. There is strong evidence from the
investigators own laboratory on the ICB and from other investigators
working with different tissues that PLA2, which acts on phospholipids to
liberate AA and lysophospholipid, plays a central role in the control of AA
required for eicosanoid biosynthesis. Based on these findings the
investigators now propose to address the following specific aims: (1)
Investigate the AA content of the major membrane phospholipids,
phospholipases (A2,C,D) activities, and the effects of various agonists on
AA release and eicosanoid biosynthesis in ICB and trabecular meshwork of
different mammalian species. (2) Investigate the mechanisms involved in
agonist-induced AA release and phospholipid source of AA in the iris
sphincter, and AA release from phospholipids in membranes isolated from
iris sphincters. Endogenous release of AA will be monitored with GLC. (3)
Investigate the regulatory role of protein kinase C in AA release and PG
synthesis in the iris sphincter. Both PKC inhibitors and down-regulation
of PKC with PDBu will be employed. (4) Purify and characterize
phospholipase(s) A2 from rabbit ICB. Activators and inhibitors of PLA2
will be employed. An attempt will be made to reconstitute the purified PLA2
with G-proteins. (5) Investigate the mechanism of the effects of in vitro
and in vivo PG receptor desensitization on basal and on agonist-induced AA
release and PG synthesis, IP3 production, cAMP formation, and on
contraction in the iris sphincter. The proposed studies will yield
important basic information about the physiological regulation of AA
release from membrane phospholipids, the link between receptor activation
and AA release, the profile of PGs produced in response to each agonist,
the mechanism of PG receptor desensitization and its cross desensitization
of other receptors, and the role of phospholipases (A2,C,D) in stimulus-
dependent release of AA in ocular tissues. Understanding the biochemical
basis for the regulation of AA liberation and PG synthesis will make their
pharmacological manipulation more plausible, and will lead to the
development of more effective anti-glaucoma and anti-inflammatory drugs.
描述(研究者摘要):本研究的长期目标
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ATA A ABDEL-LATIF其他文献
ATA A ABDEL-LATIF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ATA A ABDEL-LATIF', 18)}}的其他基金
GLYCEROLIPIDS/PROSTAGLANDINS BIOSYNTHESIS--OCULAR TISSUE
甘油脂/前列腺素生物合成——眼组织
- 批准号:
3258781 - 财政年份:1981
- 资助金额:
$ 15.23万 - 项目类别:
LIPID AND PROTEIN PO4 TURNOVER IN IRIS OF THE EYE
眼睛虹膜中脂质和蛋白质 PO4 的周转
- 批准号:
2159026 - 财政年份:1981
- 资助金额:
$ 15.23万 - 项目类别:
GLYCEROLIPIDS AND PROSTAGLANDIN SYNTHESIS IN EYE TISSUES
眼组织中甘油脂和前列腺素的合成
- 批准号:
2159047 - 财政年份:1981
- 资助金额:
$ 15.23万 - 项目类别:














{{item.name}}会员




